Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a proof-of-concept study of guselkumab + golimumab in ulcerative colitis
2018-001510-15Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab and golimumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical response. Started Nov 2018; status: completed.
02
Drugs
guselkumabgolimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-001510-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001510-15.